Global mortality from dementia: Application of a new method and results from the Global Burden of Disease Study 2019

Abstract

Introduction Dementia is currently one of the leading causes of mortality globally, and mortality due to dementia will likely increase in the future along with corresponding increases in population growth and population aging. However, large inconsistencies in coding practices in vital registration systems over time and between countries complicate the estimation of global dementia mortality. Methods We meta‐analyzed the excess risk of death in those with dementia and multiplied these estimates by the proportion of dementia deaths occurring in those with severe, end‐stage disease to calculate the total number of deaths that could be attributed to dementia. Results We estimated that there were 1.62 million (95% uncertainty interval [UI]: 0.41–4.21) deaths globally due to dementia in 2019. More dementia deaths occurred in women (1.06 million [0.27–2.71]) than men (0.56 million [0.14–1.51]), largely but not entirely due to the higher life expectancy in women (age‐standardized female‐to‐male ratio 1.19 [1.10–1.26]). Due to population aging, there was a large increase in all‐age mortality rates from dementia between 1990 and 2019 (100.1% [89.1–117.5]). In 2019, deaths due to dementia ranked seventh globally in all ages and fourth among individuals 70 and older compared to deaths from other diseases estimated in the Global Burden of Disease (GBD) study. Discussion Mortality due to dementia represents a substantial global burden, and is expected to continue to grow into the future as an older, aging population expands globally.

Short-Term Pharmacological Induction of Arterial Stiffness and Hypertension with Angiotensin II Does Not Affect Learning and Memory and Cerebral Amyloid Load in Two Murine Models of Alzheimer’s Disease

“…Limitations of this study include the fact that only male mice were evaluated, as recent epidemiological estimates indicate that women over 65 years of age have a 1 in 6 chance of developing AD compared to 1 in 11 men [ 51 ], which is largely but not entirely due to the higher life expectancy in women [ 3 ]. Secondly, future experiments should include animals from the same animal facility, since the AngII in the current experiment affected the AD murine models and respective WT controls differently, making exact comparisons more difficult to interpret.…”

“…Globally, CVD was the number one cause of death in 2019 with an estimated death toll of 17.9 million people, of which 85% were due to heart attack and stroke [ 2 ]. Dementia, on the other hand, was the seventh leading cause of death in 2019 with an estimated death toll of 1.6 million people, with Alzheimer’s disease (AD) being the most prominent dementia syndrome [ 3 ] presenting a broad range of symptoms from motor dysfunctions to psychobehavioral manifestations [ 4 ]. The most common early manifestations of AD are loss of short-term memory, visuospatial dysfunction, impaired reasoning and language dysfunction, with cerebral β-amyloid accumulation and neurofibrillary tangles as the two major neuropathological hallmarks of the disease [ 5 , 6 ].…”

Nanotherapeutics for Nose-to-Brain Drug Delivery: An Approach to Bypass the Blood Brain Barrier

“…B% Brain IN/IV is used to measure the drug accumulation in the brain from IN compared to that of IV (4)…”

“…As the brain regulates the whole body, the damage of this control center has a detrimental effect on both physical and mental health. According to the World Health Organization (WHO), death due to Alzheimer's disease and other dementias more than doubled between 2000 and 2019, making it the 7th leading cause of death globally [4]. Not only dementia but also other neurological disorders, such as stroke, epilepsy, and Parkinson's disease, are significant causes of hospitalization and mortality worldwide.…”

Ceramide/Sphingosine 1-Phosphate Axis as a Key Target for Diagnosis and Treatment in Alzheimer’s Disease and Other Neurodegenerative Diseases

“…According to the World Health Organization (WHO), 55 million people suffer from dementia worldwide, with approximately 10 million new cases diagnosed each year [ 1 , 3 ]. In 2019, approximately 1.62 million people died from dementia, making it the seventh cause of death, and the fourth one in people over 70 years of age [ 4 ]. In addition, it is estimated that AD involves an annual cost of USD 1 trillion worldwide, which, together with the exponential increase in the number of cases due to the aging of the population, represents a great burden on healthcare systems [ 1 ].…”